NIH Agreement	9 Months Ended
Sep. 30, 2011
Nih Agreement [Abstract]
Nih Agreement [Text Block]	11. NIH Agreement In May 2011 the Company entered into an amendment of a Cooperative Research and Development Agreement (“CRADA”) with the National Institute of Health (“NIH”) for the conduct of two efficacy studies utilizing the Company’s AST-915 product candidate. The Company’s commitment under the CRADA is the payment of $50,000 to the NIH and to provide a neurologist to assist the NIH in the conduct of these two efficacy studies. The term of the amended CRADA is July 1, 2011 through June 30, 2012. The Company paid the $50,000 in June 2011. The $50,000 payment is being amortized into research and development expense on a straight-line basis over the term of the CRADA. The Company recognized $12,500 of research and development expense during the nine months ended September 30, 2011. The remaining unamortized balance was $37,500 at September 30, 2011 and is recorded as a component of other current assets in the accompanying Balance Sheet as of September 30, 2011.

In May 2011 the Company entered into an amendment of a Cooperative Research and Development Agreement (“CRADA”) with the National Institute of Health (“NIH”) for the conduct of two efficacy studies utilizing the Company’s AST-915 product candidate. The Company’s commitment under the CRADA is the payment of $50,000 to the NIH and to provide a neurologist to assist the NIH in the conduct of these two efficacy studies. The term of the amended CRADA is July 1, 2011 through June 30, 2012. The Company paid the $50,000 in June 2011. The $50,000 payment is being amortized into research and development expense on a straight-line basis over the term of the CRADA. The Company recognized $12,500 of research and development expense during the nine months ended September 30, 2011. The remaining unamortized balance was $37,500 at September 30, 2011 and is recorded as a component of other current assets in the accompanying Balance Sheet as of September 30, 2011.